According to recent guidelines, endocrine therapy should be the treatment of choice for most patients with advanced or metastatic ER+, PR+/HER2 (−) breast cancer unless there is evidence of rapidly progressive visceral disease with organ dysfunction or imminent organ failure [27,28]. This evidence concerns the gene ESR1 and breast cancer.